Email this article Stimulation of kidneys’ adaptive capabilities in patients with urolithiasis
- Authors: Streltsova O.S.1, Pochtin D.P.2, Gorbunova T.A.2, Lazukin V.F.1, Sidnev I.L.1
-
Affiliations:
- Privolzhskiy Research Medical University
- Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
- Issue: Vol 9, No 3 (2019)
- Pages: 13-20
- Section: Original articles
- URL: https://ogarev-online.ru/uroved/article/view/17700
- DOI: https://doi.org/10.17816/uroved9313-20
- ID: 17700
Cite item
Abstract
Inflammatory changes in the kidney that occurred in the early postoperative period due to surgical trauma, deterioration of microcirculation, hypoxia, are significant risk factors for the development of renal function violation. The aim of this work is to study the effect of the combined drug “Uriclar” (Asfarma-Ros) on the kidneys’ adaptive capability in the early postoperative period as a response to operative trauma of patients with complicated urolithiasis. The effect of surgical intervention – percutaneous puncture nephrolithotripsy on the blood content of proteins of the acute phase of inflammation and cystatin C was studied. The results of examination of 35 patients (20 – the main group and 15 – the control group) were analyzed. The median age was 51 ± 8.4 years. 20 patients of the main group began receiving Uriclar 2 capsules (430 mg) twice a day for 5 days before surgery and continued it for 1 month after surgery. Patients from the control group in the pre- and postoperative periods didn’t receive Uriclar. The median age was 51 ± 8.4 years. There was a statistically significant increase in the level of cystatin C and changes in biochemical markers in the patients of the main group only that indicates the presence of adaptogenic effect of Uriclar. Thus, the inclusion of a combined drug Uriclar in a complex treatment of patients with urolithiasis allows disturbed biological and adaptive functions of the kidneys to be corrected in the early postoperative period.
Full Text
##article.viewOnOriginalSite##About the authors
Olga S. Streltsova
Privolzhskiy Research Medical University
Author for correspondence.
Email: strelzova_uro@mail.ru
Doctor of Medical Science, Professor of the Department of Urology named after E.V. Shakhov
Russian Federation, Nizhny NovgorodDmitry P. Pochtin
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
Email: dpochtin@mail.ru
urologist
Russian Federation, Nizhny NovgorodTatiana A. Gorbunova
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
Email: gorbunova6030@yandex.ru
Clinical Laboratory Diagnostics Doctor
Russian Federation, Nizhny NovgorodValery F. Lazukin
Privolzhskiy Research Medical University
Email: valery-laz@yandex.ru
Candidate of Medical Science, Associate Professor of the Department of Medical Physics and Informatics
Russian Federation, Nizhny NovgorodIlya L. Sidnev
Privolzhskiy Research Medical University
Email: iljasidnev@yandex.ru
student
Russian Federation, Nizhny NovgorodReferences
- Türk C, Neisius A, Petrik A, et al. EAU Guidelines on urolithiasis [Electronic resource]. European Association of Urology; 2017. 84 p. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urolithiasis_2017_10-05V2.pdf.
- Толордава Э.Р. Роль бактериальных биопленок в этиопатогенезе мочекаменной болезни: Автореф. дис. … канд. биол. наук. – М., 2014. – 27 с. [Tolordava ER. Rol’ bakterial’nyi bioplenok v etiopatogeneze mochekamennoi bolezni. [dissertation abstract] Moscow; 2014. 27 р. (In Russ.)]. Доступно по: https://dlib.rsl.ru/viewer/01005545003#?page=1. Ссылка активна на 02.06.2019.
- Liu YQ, Lu J, Hao YC, et al. [Predicting model based on risk factors for urosepsis after percutaneous nephrolithotomy. (In Chinese)]. Beijing Da Xue Xue Bao Yi Xue Ban. 2018;50(3):507-513.
- Koras O, Bozkurt IH, Yonguc T, et al. Risk factors for postoperative infectious complications following percutaneous nephrolithotomy: a prospective clinical study. Urolithiasis. 2015;43(1):55-60. https://doi.org/10.1007/s00240-014-0730-8.
- Yang T, Liu S, Hu J, et al. T. The evaluation of risk factors for postoperative infectious complications after percutaneous nephrolithotomy. Biomed Res Int. 2017;2017:4832051. https://doi.org/10.1155/2017/4832051.
- Патент РФ на изобретение RU № 2253366. Татевосян А.С., Осипов А.А., Опольский А.Б., Татевосян Т.С. Способ консервативного лечения мочекаменной болезни и предупреждения рецидивного образования камней почек. [Patent RUS № 2253366. Tatevosyan AS, Osipov AA, Opolskiy AB, Tatevosyan TS. Сonservative method for treating the cases of urolithiasis and preventing recurrent calculus formation. (In Russ.)]. Доступно по: http://www.freepatent.ru/patents/2253366. Ссылка активна на 16.05.2019.
- Казанская И.В. Фитопрепараты в детской уронефрологии // Вестник Российского общества урологов. – 2015. – № 2. – С. 18. [Kazanskaya IV. Fitopreparaty v detskoi uronefrologii. Vestnik Rossiyskogo obshchestva urologov. 2015;(2):18. (In Russ.)]
- Постановление Правительства РФ № 917 от 10.08.1998 «О Концепции государственной политики в области здорового питания населения Российской Федерации на период до 2005 года». – М., 1998. [Decree of the Government of the Russian Federation № 917 “O Kontseptsii gosudarstvennoy politiki v oblasti zdorovogo pitaniya naseleniya Rossiyskoy Federatsii na period do 2005 goda”; dated 2014 August 10. Moscow; 1998. (In Russ.)]. Доступно по: http://www.consultant.ru/cons/CGI/online.cgi?req=doc;base=EXP;n=259367;dst=100010#03399473135018607. Ссылка активна на 02.06.2019.
- Гуденко Ю.А., Казанская И.В., Лобжанидзе З.Д. Применение препарата Роватинекс в детской урологии // Экспериментальная и клиническая урология. 2013. – № 3. – С. 61–65. [Gudenko YaA, Kazanskaya IV, Lobyanidze ZB. Rovatinex usage in pediatric urology. Experimental and clinical urology. 2013;(3):61-65. (In Russ.)]
- Справочник лекарств [электронный ресурс]. Уриклар. Инструкция по применению. [Spravochnik lekarstv [Elektronnyi resurs]. Uriklar. Instruktsiya po primeneniyu. (In Russ.)]. Доступно по: http://instrukciya-otzyvy.ru/1588-uriklar-po-primeneniyu-analogi-kapsuly-tabletki-kamni-v-pochkah-profilaktika-sostav.html. Ссылка активна на 02.06.2019.
- Урология. Российские клинические рекомендации / Под ред. Аляева Ю.Г., Глыбочко П.В., Пушкаря Д.Ю. – М.: Медфорум, 2017. – 544 с. [Urologiya. Rossiiskie klinicheskie rekomendatsii. Ed. by Alyaev YuG, Glybochko PV, Pushkar’ DYu. Moscow: Medforum; 2017. 544 р. (In Russ.)]
- Вельков В.В. Цистатин С — новые возможности и новые задачи для лабораторной дигностики [электронный ресурс]. – М.: ЗАО «Диакон», 2011. – 73 с. [Velkov VV. Cystatin C: The new opportunities and new goals for laboratory diagnostics [Elektronnyi resurs]. Moscow: ZAO “DIAKON”; 2011. 73 р. (In Russ.)]. Доступно по: http://www.diakonlab.ru/files/Docs/SciArticles/Cystatin_C_Rev_Site(2).pdf. Ссылка активна на 02.06.2019.
- Клиническая лабораторная диагностика: национальное руководство. В 2 т. Т. 1 / Под ред. В.Д. Долгова, В.В. Меньшикова. – М.: ГЭОТАР-Медиа, 2012. – 928 с. [Klinicheskaya laboratornaya diagnostika: natsional’noe rukovodstvo. V 2 t. Vol. 1. Ed. by V.D. Dolgov, V.V. Men’shikov. Moscow: GEOTAR-Media; 2012. 928 р. (In Russ.)]
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
- Grubb A, Björk J, Lindström V, et al. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the cockcroft-gault formula. Scand J Clin Lab Invest. 2005;65(2):153-162. https://doi.org/10.1080/00365510510013596.
- Тарасенко А.И., Пушкарев А.М., Ракипов И.Г., и др. Биомаркеры повреждения почек при контактной уретеролитотрипсии // Урология. – 2017. – № 5. – С. 75–79. [Tarasenko AI, Pushkarev AM, Rakipov IG, et al. Biomarkers of renal injury in contact ureteral lithotripsy. Urologiia. 2017;(5):75-79. (In Russ.)]. https://doi.org/10.18565/urology.2017.5.75-79.
- Шестаев А.Ю., Протощак В.В., Паронников М.В., Киселев А.О. Комбинированный (цитратный и растительный) препарат Уриклар в дистанционной литотрипсии и метафилактике мочекаменной болезни // Урологические ведомости. – 2018. – Т. 8. – № 1. – С. 19–25. [Shestaev AYu, Protoshchak VV, Paronnikov MV, Kiselev AO. Combined (citrate and herbal) drug Uriklar in extracorporeal shock wave lithotripsy and metaphylaxis of urolithiasis. Urologicheskie vedomosti. 2018;8(1):19-25. (In Russ.)]. https://doi.org/10.17816/uroved8119-25.
- Шевченко О.П., Долгов В.В., Олиференко Г.А. Электрофорез в клинической лаборатории. – М.: Реафарм, 2006. – 160 c. [Shevchenko OP, Dolgov VV, Oliferenko GA. Elektroforez v klinicheskoi laboratorii. Moscow: Reafarm; 2006. 160 р. (In Russ.)]
Supplementary files
